Edition:
India

Genetic Technologies Ltd (GENE.OQ)

GENE.OQ on NASDAQ Stock Exchange Capital Market

0.90USD
15 Dec 2017
Change (% chg)

$-0.01 (-1.09%)
Prev Close
$0.91
Open
$0.90
Day's High
$0.97
Day's Low
$0.90
Volume
9,740
Avg. Vol
28,854
52-wk High
$1.38
52-wk Low
$0.70

Summary

Name Age Since Current Position

Malcolm Brandon

66 2012 Non-Executive Chairman of the Board

Eutillio Buccilli

2015 Chief Executive Officer, Executive Director

Kevin Fischer

2016 Chief Financial Officer, Company Secretary

Mark Ostrowski

50 2014 President of Phenogen Sciences Inc

Richard Allman

53 2012 Scientific Director

M. Luisa Ashdown

57 2012 Director of Global Licensing and Intellectual Property

Susan Gross

2016 Senior Medical Director

Diana Newport

56 2013 Quality and Business Operations Director

Grahame Leonard

2013 Director

Paul Kasian

2013 Non-Executive Director

Lindsay Wakefield

2014 Non-Executive Independent Director

Biographies

Name Description

Malcolm Brandon

Dr. Malcolm (Mal) Roy Brandon, BScAgr, Ph.D., is Chairman of the Board at Genetic Technologies Limited. Dr. Brandon was appointed to the Board on October 5, 2009 and as its Chairman on November 28, 2012. He also serves as Chairman of the Company’s Audit Committee. He has spent his career in the biotech and life sciences sector where he has over 35 years experience in commercially focused research and development and in building successful companies which have commercialised a wide range of technologies. As the founding director of the Centre for Animal Biotechnology, a research arm within the University of Melbourne Veterinary Science School, he was responsible for fund raising and the development of many agricultural technologies and products. Dr. Brandon was a co-founder and Director of Stem Cell Sciences Ltd. and Smart Drug Systems Inc. and is the Chairman of genetics and artificial animal breeding company Clone International which uses cloning technologies to breed cattle, sheep and horses and to preserve the genetics of elite animals. Dr. Brandon also serves as Chairman of the Company’s Canadian-listed subsidiary, Gtech International Resources Limited.

Eutillio Buccilli

Mr. Eutillio Buccilli is Chief Executive Officer, Executive Director of Genetic Technologies Limited. He has been appointed to the position of Executive Director of the Company with effect from 12 June 2015. Mr. Buccilli joined the Company in June 2014 as Chief Financial Officer. In November 2014, Mr. Buccilli was appointed to the position of Chief Operating Officer and Chief Financial Officer and was subsequently appointed Chief Executive Officer in February 2015. Mr. Buccilli has more than 35 years of senior management experience in the financial services, contracting and recruitment, property and retail industries in Australia and the U.S. He has held senior management positions with blue chip corporations such as General Electric (“GE”), Computer Science Corporation, Coles Myer and Challenger Limited. Whilst at GE, Mr. Buccilli was seconded to the U.S., where he worked at the GE Capital Headquarters located in Stamford Connecticut.

Kevin Fischer

Mr. Kevin Fischer is Chief Financial Officer, Company Secretary of the Company. With over ten years in senior finance roles with successful diagnostic companies, such as QIAGEN and Cellestis, Mr. Fischer is well qualified to take on the roles of CFO and joint Company Secretary. Mr. Fischer is a CPA and Chartered Secretary who has significant experience in the administration, financial management and reporting for international operations similar to those of Genetic Technologies.

Mark Ostrowski

Mr. Mark Ostrowski has been appointed as President of Phenogen Sciences Inc., the subsidiary of Genetic Technologies Ltd., effect from 25 November 2014. Mr. Ostrowski joined the Company in September 2012, and was appointed to the position of Senior VP Sales and Marketing. Mr Ostrowski possesses over 20 years of sales and marketing experience in molecular diagnostics having served in senior managerial positions at companies focused on women’s. health and oncology, including as Director of Sales Operations at Myriad Genetics (NASDAQ: MYGN) and Director of Managed Care Services at DIANON Systems (NASDAQ: DIAN). Prior to joining the Company, Mr. Ostrowski’s career spanned both early stage and established biomedical companies. During his tenure at Myriad, he had comprehensive exposure to all aspects of sales and marketing, managing a sales force of over 200 representatives, demonstrating average annual revenue growth of over 50%, and generating new strategic divisions and best practice policies.

Richard Allman

Dr. Richard Allman, Ph.D serves as a Scientific Director at Genetic Technologies Limited. He has over 20 years of scientific and research experience in both the academic arena in the UK and the commercial sector in Australia. He has wide experience in research leadership, innovation management, and intellectual property strategy, covering oncology, diagnostics, and product development. Prior to entering the biotech sector, Dr. Allman’s academic career encompassed oncology research, drug development, and assay design.

M. Luisa Ashdown

Ms. M. Luisa Ashdown serves as Director of Global Licensing and Intellectual Property at Genetic Technologies Limited. e has expertise in the area of genetics and immunology and has been with the Company since it started in 1989 during which time she was instrumental in the establishment of the Company’s laboratory capability and DNA testing services. She has since served in various roles including as Director of several of GTG’s subsidiaries. For over a decade, she has been involved in Licensing and Property defence and management.

Susan Gross

Dr. Susan J. Gross, M.D. is Senior Medical Director of the Company. She received her medical degree from the University of Toronto, Ontario, Canada, where she completed her residency in Obstetrics and Gynecology, as well as a fellowship in Maternal Fetal Medicine and a second residency/fellowship in Medical Genetics at the University of Tennessee (Memphis). She is board certified in both Obstetrics and Gynecology and Medical Genetics and is a Professor of Clinical Obstetrics & Gynecology, Women's Health, Pediatrics and Genetics at the Albert Einstein College of Medicine. She served as past division director for the Division of Reproductive Genetics at Montefiore Medical Center as well as Chairperson of the Department of Obstetrics and Gynecology and founder of the Human Genetics Laboratory at Jacobi Medical Center. Dr. Gross has spent decades not only in research and medical education, but also direct patient care, overseeing both large and small practice systems. She has worked on national and international guideline committees and lectured and published extensively on screening and genetic testing with a focus on new technologies and public health policy. She was previously the Chief Medical Officer of Natera Inc., a public genomic diagnostics company and is now President of SJG Advisors LLC, a company that provides comprehensive medical affairs and digital media expertise to the diagnostics industry.

Diana Newport

Ms. Diana Newport serves as a Quality and Business Operations Director at Genetic Technologies Limited in September 2013. She comes to the Company with extensive international Quality Systems and operational experience in the highly regulated industries of food and pharmaceutical. The Company will benefit from her experience gained from recent senior roles within the CSL quality control laboratories.

Grahame Leonard

Mr. Grahame James Leonard is Director of Genetic Technologies Ltd effective November 29, 2013. He is a qualified Chartered Accountant and a Barrister and Solicitor of the Supreme Court of Victoria. He began his professional life in various positions in the steel industry, having worked for 20 years with Lysaght (BHP), gaining invaluable training and experience in all facets of management, honing his skills in negotiating, training, planning and communication. He subsequently accepted a senior executive position as Divisional General Manager with Nylex, which evolved into the BTR Nylex group. On his return from establishing a distribution structure in USA in 1986, Mr. Leonard became Chief Operating Officer and Finance Director of the Australian subsidiary of the publishing multinational, The Thomson Corporation. Mr. Leonard’s current professional positions include Commissioner, Victorian Multicultural Commission; Chairman, Escrow Angel Pty. Ltd., Diffuze Pty. Ltd. and Design Quotes Pty. Ltd.; Director, Nirosoft Australia Pty. Ltd. (the Australian arm of the Israeli suppliers of advanced water and waste water systems and services, Sunnymarsh Pty. Ltd. and Viva Tags Pty. Ltd.). His numerous community positions include member Committee of Management, Past President and Honorary Life Member Executive Council of Australian Jewry; Director and Immediate Past Honorary Chief Executive Officer of Transparency International Australia (the Australian arm of the international anti-corruption watchdog), and member Governance and Steering Committees on the Jewish Community Demographic Survey Project. In 2003, Mr. Leonard was awarded the Centenary Medal, instituted to commemorate the centenary of Federation of Australia, for community service and, in 2008, he was appointed a Member of the Order of Australia.

Paul Kasian

Dr. Paul Alexander Kasian is Non-Executive Director of Genetic Technologies Ltd. Dr. Kasian is an experienced executive director with demonstrated domestic and international success in funds management, encompassing senior leadership, investment and risk roles. Previously, Dr. Kasian has held senior leadership positions in a number of investment groups, including Chief Investment Officer at HSBC Asset Management; Head of HSBC Global Financial Team; Founding Director Accordius and Founding Director Wallara Asset Management. Dr. Kasian has funds management experience in Australia leading investment in the healthcare and life sciences sector. He was previously a Project Leader at ICI Australia providing advice on biotech projects and acquisitions. He holds a Doctorate in Philosophy in Microbiology and a Master of Business Administration, both from the University of Melbourne.

Lindsay Wakefield

Dr. Lindsay Peter Wakefield is Non-Executive Independent Director of the Company. Dr. Wakefield started Safetech in 1985. In 1993, he left Medicine to become the fulltime CEO of the Company. Over the next 25 years Safetech became a force in the Australian material handling and lifting equipment market, designing and manufacturing a wide range of industrial products. In 2006, Safetech was awarded the Telstra Australian National Business of the Year. In 2013, Safetech merged to become STS (Safetech Tieman Solutions) which is Australia’s largest manufacturer and supplier of dock equipment, freight hoists and custom lifting solutions. Dr. Wakefield continues as Managing Director of STS and has been a keen Biotech investor for past 20 years, often at a mezzanine level.